BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27805011)

  • 1. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
    Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
    Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy.
    Vesely S; Jarolim L; Schmidt M; Do Carmo Silva J; Duskova K; Babjuk M
    Scand J Urol; 2017 Apr; 51(2):114-119. PubMed ID: 28635569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
    Schroeck FR; Sun L; Freedland SJ; Jayachandran J; Robertson CN; Moul JW
    Prostate Cancer Prostatic Dis; 2008; 11(4):371-6. PubMed ID: 18427570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?
    Simon RM; Howard LE; Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Vidal AC
    BJU Int; 2016 Jun; 117(6):897-903. PubMed ID: 26010251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
    De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
    BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
    Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
    Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K; Niwa N; Hattori S; Takeda T; Morita S; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Asanuma H; Oya M
    Urol Oncol; 2018 Jul; 36(7):341.e9-341.e14. PubMed ID: 29730065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy.
    Godoy G; Tareen BU; Lepor H
    BJU Int; 2009 Dec; 104(11):1610-4. PubMed ID: 19549257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
    Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
    World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.